Harmony Biosciences Holdings, Inc.
HRMY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001802665
In the last 90 days, Harmony Biosciences Holdings, Inc. insiders filed 0 open-market purchases and 2 sales; 328 institutions reported holding it in 13F filings for Q2 2026, worth $1.97B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $3.11M in total
- 2
- 13F holdersQ2 2026, +20 vs. previous quarter
- 328
- 13F valueReported value at the end of Q2 2026
- $1.97B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding HRMY, Q2 2026
No superinvestor reported holding HRMY at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Harmony Biosciences Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:48 PM ET | Sep 16-18 | 2 days | Budur KumarCHIEF MEDICAL OFFICER | SSale | −38.5K | $43.05 | −$1.66M | −74.6%13.1K after | 3 lots |
| Sep 9, 2026 (view filing)5:12 PM ET | Sep 4-8 | 5 days | Budur KumarCHIEF MEDICAL OFFICER | SSale | −34.0K | $42.80 | −$1.45M | −72.1%13.1K after | 4 lots |
| Jan 28, 2026 (view filing) | Jan 26 | 2 days | Kapadia SandipCHIEF FINANCIAL OFFICER | SSale | −3.75K | $37.15 | −$139.2K | −13.3%24.5K after | 10b5-1 |
| Jan 20, 2026 (view filing) | Jan 15 | 5 days | Kapadia SandipCHIEF FINANCIAL OFFICER | SSale | −21.0K | $35.92 | −$752.9K | −100.0%0 after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 12 | 5 daysLate | Dayno Jeffrey M.PRESIDENT, CEO | SSale | −25.9K | $40.11 | −$1.04M | −100.0%0 after | 2 lots10b5-1 |
| Dec 9, 2025 (view filing) | Dec 5 | 4 days | Kapadia SandipCHIEF FINANCIAL OFFICER | SSale | −20.0K | $39.54 | −$790.8K | −100.0%0 after | 10b5-1 |
| Nov 25, 2025 (view filing) | Nov 21 | 4 days | Kapadia SandipCHIEF FINANCIAL OFFICER | SSale | −3.43K | $35.00 | −$119.9K | −100.0%0 after | 10b5-1 |
| Aug 19, 2025 (view filing) | Aug 15 | 4 days | Kapadia SandipCHIEF FINANCIAL OFFICER | SSale | −21.6K | $36.50 | −$787.4K | −100.0%0 after | 10b5-1 |
| Apr 3, 2025 (view filing) | Apr 1 | 2 days | Kapadia SandipCHIEF FINANCIAL OFFICER | SSale | −6.99K | $32.55 | −$227.4K | −100.0%0 after | 2 lots10b5-1 |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Dierks JeffreyCHIEF COMMERCIAL OFFICER | SSale | −4.87K | $32.67 | −$159.1K | −100.0%0 after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Harmony Biosciences Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,101,965 | $258.6M | 0.00% | +31,930+0.5% | Added |
| FMR LLC | 3,574,115 | $130.1M | 0.01% | +416,476+13.2% | Added |
| Vanguard Portfolio Management LLC | 2,880,489 | $104.9M | 0.00% | +166,136+6.1% | Added |
| American Century Companies Inc | 2,539,512 | $92.5M | 0.04% | +434,333+20.6% | Added |
| Dimensional Fund Advisors LP | 2,393,588 | $87.1M | 0.02% | +317,078+15.3% | Added |
| Vanguard Capital Management LLC | 2,105,053 | $76.6M | 0.00% | +2,738+0.1% | Added |
| LSV Asset Management | 2,061,242 | $75.0M | 0.14% | +36,099+1.8% | Added |
| State Street Corp | 1,859,322 | $67.7M | 0.00% | +74,960+4.2% | Added |
| Armistice Capital, LLC | 1,564,000 | $56.9M | 1.58% | −60,000−3.7% | Reduced |
| Geode Capital Management, LLC | 1,442,649 | $52.5M | 0.00% | +119,929+9.1% | Added |